Many tumour types have been reported to have deletion of 9p21 (rets 1-6). A candidate target suppressor gene, p16 (p16INK4a/MTS-1/CDKN2), was recently identified within the commonly deleted region in tumour cell lines7,8. An increasing and sometimes conflicting body of data has accumulated regarding the frequency of homozygous deletion and the importance of p16 in primary tumours. We tested 545 primary tumours by microsatellite analysis with existing and newly cloned markers around the p16 locus. We have now found that small homozygous deletions represent the predominant mechanism of inactivation at 9p21 in bladder tumours and are present in other tumour types, including breast and prostate cancer. Moreover, fine mapping of these deletions implicates a 170 kb minimal region that includes p16 and excludes p15.
Subscribe to Journal
Get full journal access for 1 year
only $18.75 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Diaz, M.O. et al. Deletions of interferon genes in acute lymphoblastic leukemia. N. Engl. J. Med. 332, 77–82 (1990).
Fountain, J.W. et al. Homozygous deletions within human chromosome band 9p21 in melanoma. Proc. natn. Acad. Sci. U.S.A. 89, 10557–10561 (1992).
James, C.D. et al. Chromosome 9 deletion mapping reveals interferon a and interferon β-1 gene deletions in human glial tumors. Cancer Res. 51, 1684–1688 (1991).
Olopade, O.I. et al. Homozygous loss of the interferon genes defines the critical region on 9p that is deleted in lung cancers. Cancer Res. 53, 2410–2415 (1993).
Cairns, P., Tokino, K., Eby, Y. & Sidransky, D. Homozygous deletions of 9p21 in primary human bladder tumors detected by comparative multiplex polymerase chain reaction. Cancer Res. 54, 1422–1424 (1994).
van der Riet, P. et al. Frequent loss of chromosome 9p21 -22 early in head and neck cancer progression. Cancer Res. 54, 1156–1158 (1994).
Kamb, A. et al. A cell cycle regulator potentially involved in genesis of many tumor types. Science 264, 436–440 (1994).
Nobori, T. et al. Deletions of the cyclin-dependent kinase-4 inhibitor gene in multiple human cancers. Nature 368, 753–756 (1994).
Knudson, A.G., Jr., Hethcote, H.W. & Brown, B.W. Mutation and childhood cancer: a probabilistic model for the incidence of retinoblastoma. Proc. natn. Acad. Sci. U.S.A. 72, 5116–5120 (1975).
Hussussian, C.J. et al. Germline p16 mutations in familial melanoma. Nature Genet. 8, 15–21 (1994).
Mori, T. et al. Frequent somatic mutation of the MTS1/CDK4I (multiple tumor suppressor/cyclin-dependent kinase 4 inhibitor) in esophageal squamous cell carcinoma. Cancer Res. 54, 3396–3397 (1994).
Caldas, C. et al. Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nature Genet 8, 27–32 (1994).
Hayashi, N., Sugimoto, Y., Tsuchiya, E., Ogawa, M. & Nakamura, Y. Somatic mutations of the MTS1 (multiple tumor suppressor) CDK41 (cyclin-dependent kinase-4 inhibitor) gene in human primary non-small cell lung carcinomas. Biochem. biophys. Res. Commun. 202, 1426–1430 (1994).
Kamb, A. et al. Analysis of the p16 gene (CDKA/2) as a candidate for the chromosome 9p melanoma susceptibility locus. Nature Genet. 8, 23–26 (1994).
Xu, L. et al. Rarity of somatic and germline mutations of the cyclin-dependent kinase 4 inhibitor gene, CDK4I, in melanoma. Cancer Res. 54, 5269–5272 (1994).
Zhou, X. et al. The MTS1 gene is frequently mutated in primary human esophageal tumors. Oncogene 9, 3737–3747 (1994).
Okamoto, A. et al. Mutations in the p16(INK4)/MTS1/CDKN2,p15(INK4B)/ MTS2, and p18 genes in primary and metastatic lung cancer. Cancer Res. 55, 1448–1451 (1995).
Cairns, P. et al. Rates of p16(MTS1) mutations in primarytumors with 9p loss. Science 265, 415–416 (1994).
Xu, L., et al. Mutational analysis of CDKN2 (MTS1/P16INK4) in human breast carcinomas. Cancer Res. 54, 5262–5264 (1994).
Jen, J. et al. Deletion of p16 and p15 genes in brain tumors. Cancer Res. 54, 6353–6358 (1994).
Middleton-Price, H., Spurr, N., Hall, A. & Malcolm, S. N-ras-like sequences on chromosomes 9,6 and 22 with a polymorphism at the chromosome 9 locus. Ann. hum. Genet. b, 189–195 (1988).
Sauter, G. et al. Chromosome-9 loss detected by fluorescence in situ hybridization in bladder cancer. Int. J. Cancer 64, 99–103 (1995).
Kamb, A., Liu, Q., Harshman, K. & Tavtigian, S. Rates of p16(MTS1) mutations in primary tumors with 9p loss. Science 265, 416–417 (1994).
Lefebvre, S. et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell 80, 155–165 (1995).
Roy, N. et al. The gene for neuronal apoptosis inhibitory protein is partially deleted in individuals with spinal muscular atrophy. Cell 80, 167–178 (1995).
Cairns, P., Shaw, M.E. & Knowles, M.A. Initiation of bladder cancer may involve deletion of a tumor suppressor gene on chromosome 9. Oncogene 8, 1083–1085 (1993).
Merlo, A., et al. CpG island methylation is associated with transcriptional silencing of the tumour suppressor CDKN2/p16 in human cancers. Nature Med. 1, 686–692 (1995).
Weaver-Feldhaus, J. et al. Localization of a putative tumor suppressor gene by using homozygous deletions in melanomas. Proc. natn. Acad. Sci. U.S.A. 91, 7563–7567 (1994).
Zhang, J., Meltzer, P., Jenkins, R., Guan, X.Y., Trent, J. Application of chromosome microdissection probes for elucidation of BCR-ABL fusion and variant Philadelphia chromosome translocations in chronic myelogenous leukemia. Blood 81, (12), 3365–3371 (1993).
About this article
Cite this article
Cairns, P., Polascik, T., Eby, Y. et al. Frequency of homozygous deletion at p16/CDKN2 in primary human tumours. Nat Genet 11, 210–212 (1995) doi:10.1038/ng1095-210
Surgical and Experimental Pathology (2019)
Immunohistochemical characterization of benign activation of junctional melanocytes and melanoma in situ of the nail unit
Journal of Cutaneous Pathology (2019)
Computational assessment of somatic and germline mutations of p16INK4a: Structural insights and implications in disease
Informatics in Medicine Unlocked (2019)
Analysis of head and neck carcinoma progression reveals novel and relevant stage-specific changes associated with immortalisation and malignancy
Scientific Reports (2019)
The American Journal of Surgical Pathology (2019)